RxDoctor Payments Data

Raul Schwartzman, MD

Cardiovascular Disease · Avon, OHNPI 1306821152

Payments from drug & device makers

$899in general payments, 2019–2025

Across 37 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$263
  • Abbott$127
  • Johnson & Johnson$117
  • Regeneron Healthcare Solutions, Inc.$70
  • Pfizer$67
  • Novartis$48
  • plus $207 from 9 others

What the payments were for

  • Food & beverage$899100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$899 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$81,998
Medicare patients
1,203
Services billed
1,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban166$222,558
JardianceEmpagliflozin56$78,414
XareltoRivaroxaban68$66,456
EntrestoSacubitril/Valsartan46$64,026
Repatha SureclickEvolocumab44$28,250
BrilintaTicagrelor15$10,746
Metoprolol Succinate431$5,637
Atorvastatin Calcium472$5,019
Rosuvastatin Calcium173$3,062
Ezetimibe55$1,777
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide102$1,531
Losartan Potassium126$1,438
Flecainide Acetate23$1,262
Amiodarone Hcl20$938
Amlodipine Besylate180$925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$222,558166 claims
Boehringer IngelheimJardiance$14$78,41456 claims
Johnson & JohnsonXarelto$117$66,45668 claims
NovartisEntresto$48$64,02646 claims
AstraZenecaBrilinta$17$10,74615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Avon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →